{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T00:31:56Z","timestamp":1794357116044,"version":"4.9.0"},"reference-count":177,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T00:00:00Z","timestamp":1638144000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Aging Neurosci."],"abstract":"<jats:p>Parkinson\u2019s disease (PD) is the second most common neurodegenerative disease. Cognitive impairment is one of the key non-motor symptoms of PD, affecting both mortality and quality of life. However, there are few experimental studies on the pathology and treatments of PD with mild cognitive impairment (PD-MCI) and PD dementia (PDD) due to the lack of representative models. To identify new strategies for developing representative models, we systematically summarized previous studies on PD-MCI and PDD and compared differences between existing models and diseases. Our initial search identified 5432 articles, of which 738 were duplicates. A total of 227 articles met our inclusion criteria and were included in the analysis. Models fell into three categories based on model design: neurotoxin-induced, transgenic, and combined. Although the neurotoxin-induced experimental model was the most common type that was used during every time period, transgenic and combined experimental models have gained significant recent attention. Unfortunately, there remains a big gap between ideal and actual experimental models. While each model has its own disadvantages, there have been tremendous advances in the development of PD models of cognitive impairment, and almost every model can verify a hypothesis about PD-MCI or PDD. Finally, our proposed strategies for developing novel models are as follows: a set of plans that integrate symptoms, biochemistry, neuroimaging, and other objective indicators to judge and identify that the novel model plays a key role in new strategies for developing representative models; novel models should simulate different clinical features of PD-MCI or PDD; inducible \u03b1-Syn overexpression and SH-SY5Y-A53T cellular models are good candidate models of PD-MCI or PDD.<\/jats:p>","DOI":"10.3389\/fnagi.2021.745438","type":"journal-article","created":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T13:21:27Z","timestamp":1638364887000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Experimental Models of Cognitive Impairment for Use in Parkinson\u2019s Disease Research: The Distance Between Reality and Ideal"],"prefix":"10.3389","volume":"13","author":[{"given":"Yaohua","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajun","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxiao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peipei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zifeng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqian","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YiChun","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongfeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiling","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,11,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"S144","DOI":"10.1016\/j.parkreldis.2015.09.034","article-title":"Cognitive impairment in Parkinson\u2019s disease and dementia with Lewy bodies.","volume":"22","author":"Aarsland","year":"2016","journal-title":"Parkinsonism Relat. Disord."},{"key":"B2","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nrneurol.2017.27","article-title":"Cognitive decline in Parkinson disease.","volume":"13","author":"Aarsland","year":"2017","journal-title":"Nat. Rev. Neurol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jns.2009.08.034","article-title":"The epidemiology of dementia associated with Parkinson disease.","volume":"289","author":"Aarsland","year":"2010","journal-title":"J. Neurol. Sci."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/antiox9040304","article-title":"The aqueous extract from Ceratonia siliqua leaves protects against 6-hydroxydopamine in zebrafish: understanding the underlying mechanism.","volume":"9","author":"Abidar","year":"2020","journal-title":"Antioxidants (Basel)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.nlm.2017.05.001","article-title":"Human LRRK2 G2019S mutation represses post-synaptic protein PSD95 and causes cognitive impairment in transgenic mice.","author":"Adeosun","year":"2017","journal-title":"Neurobiol. Learn. Mem."},{"key":"B6","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1080\/07315724.2019.1683379","article-title":"Alzheimer\u2019s disease and Parkinson\u2019s disease: a nutritional toxicology perspective of the impact of oxidative stress, mitochondrial dysfunction, nutrigenomics and environmental chemicals.","volume":"39","author":"Agnihotri","year":"2020","journal-title":"J. Am. Coll. Nutr."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.22038\/ijbms.2016.7911","article-title":"Estrogen agonist genistein differentially influences the cognitive and motor disorders in an ovariectomized animal model of Parkinsonism.","volume":"19","author":"Arbabi","year":"2016","journal-title":"Iran. J. Basic Med. Sci."},{"key":"B8","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s11010-019-03531-w","article-title":"Repetitive transcranial magnetic stimulation protects mice against 6-OHDA-induced Parkinson\u2019s disease symptoms by regulating brain amyloid \u03b2(1-42) level.","volume":"458","author":"Ba","year":"2019","journal-title":"Mol. Cell. Biochem."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1001\/jamaneurol.2015.1449","article-title":"Cerebrospinal fluid patterns and the risk of future dementia in early, incident Parkinson disease.","volume":"72","author":"B\u00e4ckstr\u00f6m","year":"2015","journal-title":"JAMA Neurol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/mds.27902","article-title":"Prevalence and clinical aspects of mild cognitive impairment in Parkinson\u2019s disease: a meta-analysis.","volume":"35","author":"Baiano","year":"2020","journal-title":"Mov. Disord."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.00218","article-title":"Parkinson\u2019s disease and the environment.","volume":"10","author":"Ball","year":"2019","journal-title":"Front. Neurol."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2019.134438","article-title":"Edaravone-caffeine combination for the effective management of rotenone induced Parkinson\u2019s disease in rats: an evidence based affirmative from a comparative analysis of behavior and biomarker expression.","volume":"711","author":"Bandookwala","year":"2019","journal-title":"Neurosci. Lett."},{"key":"B13","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.neuron.2019.10.010","article-title":"Amyloid-Beta (A\u03b2) plaques promote seeding and spreading of alpha-synuclein and tau in a mouse model of lewy body disorders with A\u03b2 pathology.","volume":"105","author":"Bassil","year":"2020","journal-title":"Neuron"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/1028415x.2020.1815331","article-title":"Vitamin D attenuated 6-OHDA-induced behavioural deficits, dopamine dysmetabolism, oxidative stress, and neuro-inflammation in mice.","volume":"23","author":"Bayo-Olugbami","year":"2020","journal-title":"Nutr. Neurosci."},{"key":"B15","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.neuroscience.2016.05.041","article-title":"The impact of biological sex and sex hormones on cognition in a rat model of early, pre-motor Parkinson\u2019s disease.","volume":"345","author":"Betancourt","year":"2017","journal-title":"Neuroscience"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/161092","article-title":"Neuroprotective properties of the standardized extract from Camellia sinensis (Green Tea) and its main bioactive components, epicatechin and epigallocatechin gallate, in the 6-OHDA model of Parkinson\u2019s disease.","volume":"2015","author":"Bitu Pinto","year":"2015","journal-title":"Evid. Based Complement. Alternat. Med."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21228535","article-title":"Modeling Parkinson\u2019s disease neuropathology and symptoms by intranigral inoculation of preformed human \u03b1-synuclein oligomers.","volume":"21","author":"Boi","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s00702-019-02137-2","article-title":"High discriminatory ability of peripheral and CFSF biomarkers in Lewy body diseases.","volume":"127","author":"Bougea","year":"2020","journal-title":"J. Neural Transm. (Vienna)"},{"key":"B19","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.neuropharm.2017.10.032","article-title":"Preclinical profile of a dopamine D1 potentiator suggests therapeutic utility in neurological and psychiatric disorders.","volume":"128","author":"Bruns","year":"2018","journal-title":"Neuropharmacology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1007\/s00213-020-05566-0","article-title":"Novel, non-nitrocatechol catechol-O-methyltransferase inhibitors modulate dopamine neurotransmission in the frontal cortex and improve cognitive flexibility.","volume":"237","author":"Byers","year":"2020","journal-title":"Psychopharmacology (Berl.)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1002\/syn.21722","article-title":"Rearrangement of the dendritic morphology of the neurons from prefrontal cortex and hippocampus after subthalamic lesion in Sprague-Dawley rats.","volume":"68","author":"Camacho-Abrego","year":"2014","journal-title":"Synapse"},{"key":"B22","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.bbr.2017.04.028","article-title":"Exposure to an enriched environment facilitates motor recovery and prevents short-term memory impairment and reduction of striatal BDNF in a progressive pharmacological model of parkinsonism in mice.","volume":"328","author":"Camp\u00ealo","year":"2017","journal-title":"Behav. Brain Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s12011-018-1380-4","article-title":"Mercury involvement in neuronal damage and in neurodegenerative diseases.","volume":"187","author":"Cariccio","year":"2019","journal-title":"Biol. Trace Elem. Res."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1326-8-14","article-title":"Behavioral characterization of the 6-hydroxidopamine model of Parkinson\u2019s disease and pharmacological rescuing of non-motor deficits.","volume":"8","author":"Carvalho","year":"2013","journal-title":"Mol. Neurodegener."},{"key":"B25","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.bbr.2012.01.016","article-title":"Lithium and valproate prevent olfactory discrimination and short-term memory impairments in the intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) rat model of Parkinson\u2019s disease.","volume":"229","author":"Castro","year":"2012","journal-title":"Behav. Brain. Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1002\/mds.28191","article-title":"Evaluating the Role of SNCA, LRRK2, and GBA in Chinese patients with Early-Onset Parkinson\u2019s disease.","volume":"35","author":"Chen","year":"2020","journal-title":"Mov. Disord."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21072464","article-title":"Historical perspective: models of Parkinson\u2019s disease.","volume":"21","author":"Chia","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20030696","article-title":"The Role of NOX4 in Parkinson\u2019s disease with dementia.","volume":"20","author":"Choi","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/srep44989","article-title":"Conditional deletion of Ndufs4 in dopaminergic neurons promotes Parkinson\u2019s disease-like non-motor symptoms without loss of dopamine neurons.","volume":"7","author":"Choi","year":"2017","journal-title":"Sci. Rep."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.parkreldis.2014.07.008","article-title":"Abnormal MoCA and normal range MMSE scores in Parkinson disease without dementia: cognitive and neurochemical correlates.","volume":"20","author":"Chou","year":"2014","journal-title":"Parkinsonism Relat. Disord."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0202770","article-title":"Charting the onset of Parkinson-like motor and non-motor symptoms in nonhuman primate model of Parkinson\u2019s disease.","volume":"13","author":"Choudhury","year":"2018","journal-title":"PLoS One"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.61590","article-title":"Genetic disruption of WASHC4 drives endo-lysosomal dysfunction and cognitive-movement impairments in mice and humans.","volume":"10","author":"Courtland","year":"2021","journal-title":"Elife"},{"key":"B33","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.brainresbull.2017.05.014","article-title":"Fluvoxamine maleate effects on dopamine signaling in the prefrontal cortex of stressed Parkinsonian rats: implications for learning and memory.","volume":"132","author":"Dall\u00e9","year":"2017","journal-title":"Brain Res. Bull."},{"key":"B34","doi-asserted-by":"publisher","first-page":"114","DOI":"10.2174\/1567202611666140318114037","article-title":"A PPAR-\u03b2\/\u03b4 agonist is neuroprotective and decreases cognitive impairment in a rodent model of Parkinson\u2019s disease.","volume":"11","author":"Das","year":"2014","journal-title":"Curr. Neurovasc. Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.brainres.2009.01.028","article-title":"Interaction between nicotinic and dopaminergic therapies on cognition in a chronic Parkinson model.","volume":"1262","author":"Decamp","year":"2009","journal-title":"Brain Res."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.2174\/18715273113129990074","article-title":"Multiple intranigral unilateral LPS infusion protocol generates a persistent cognitive impairment without cumulative dopaminergic impairment.","volume":"12","author":"Delattre","year":"2013","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"B37","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2741\/E835","article-title":"Myricetin attenuates neurodegeneration and cognitive impairment in Parkinsonism.","volume":"10","author":"Dhanraj","year":"2018","journal-title":"Front. Biosci. (Elite Ed.)"},{"key":"B38","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/s0165-0173(01)00067-4","article-title":"Applications of the Morris water maze in the study of learning and memory.","volume":"36","author":"D\u2019Hooge","year":"2001","journal-title":"Brain Res. Brain Res. Rev."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.tox.2020.152437","article-title":"Poloxamer 188-mediated anti-inflammatory effect rescues cognitive deficits in paraquat and maneb-induced mouse model of Parkinson\u2019s disease.","volume":"436","author":"Ding","year":"2020","journal-title":"Toxicology"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1002\/jnr.23258","article-title":"REM sleep deprivation generates cognitive and neurochemical disruptions in the intranigral rotenone model of Parkinson\u2019s disease.","volume":"91","author":"Dos Santos","year":"2013","journal-title":"J. Neurosci. Res."},{"key":"B41","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1002\/mds.21844","article-title":"Diagnostic procedures for Parkinson\u2019s disease dementia: recommendations from the movement disorder society task force.","volume":"22","author":"Dubois","year":"2007","journal-title":"Mov. Disord."},{"key":"B42","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/mds.25352","article-title":"Magnetic resonance imaging: a biomarker for cognitive impairment in Parkinson\u2019s disease?","volume":"28","author":"Duncan","year":"2013","journal-title":"Mov. Disord."},{"key":"B43","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.neures.2014.11.002","article-title":"Partial dopaminergic denervation-induced impairment in stimulus discrimination acquisition in parkinsonian rats: a model for early Parkinson\u2019s disease.","volume":"92","author":"Eagle","year":"2015","journal-title":"Neurosci. Res."},{"key":"B44","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.cell.2015.08.069","article-title":"Lack of neuronal IFN-\u03b2-IFNAR causes Lewy body- and Parkinson\u2019s disease-like dementia.","volume":"163","author":"Ejlerskov","year":"2015","journal-title":"Cell"},{"key":"B45","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s12640-021-00356-8","article-title":"Neurotoxin-induced rodent models of Parkinson\u2019s disease: benefits and drawbacks.","volume":"39","author":"El-Gamal","year":"2021","journal-title":"Neurotox Res."},{"key":"B46","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/neu.20047","article-title":"6-hydroxydopamine lesions in anuran amphibians: a new model system for Parkinson\u2019s disease?","volume":"60","author":"Endepols","year":"2004","journal-title":"J. Neurobiol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/nan.12501","article-title":"Differential insular cortex subregional vulnerability to \u03b1-synuclein pathology in Parkinson\u2019s disease and dementia with Lewy bodies.","volume":"45","author":"Fathy","year":"2019","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s002130051148","article-title":"Spatial memory improvement by levodopa in parkinsonian MPTP-treated monkeys.","volume":"147","author":"Fern\u00e1ndez-Ruiz","year":"1999","journal-title":"Psychopharmacology (Berl.)"},{"key":"B49","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jneumeth.2005.04.005","article-title":"Comparison of bilaterally 6-OHDA- and MPTP-lesioned rats as models of the early phase of Parkinson\u2019s disease: histological, neurochemical, motor and memory alterations.","volume":"148","author":"Ferro","year":"2005","journal-title":"J. Neurosci. Methods"},{"key":"B50","doi-asserted-by":"publisher","first-page":"741","DOI":"10.3109\/07420528.2012.762011","article-title":"Lack of long-term changes in circadian, locomotor, and cognitive functions in acute and chronic MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mouse models of Parkinson\u2019s disease.","volume":"30","author":"Fifel","year":"2013","journal-title":"Chronobiol. Int."},{"key":"B51","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1021\/acschemneuro.5b00253","article-title":"Clioquinol improves cognitive, motor function, and microanatomy of the alpha-synuclein hA53T transgenic mice.","volume":"7","author":"Finkelstein","year":"2016","journal-title":"ACS Chem. Neurosci."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/j.neurobiolaging.2006.06.013","article-title":"Age-dependent cognitive decline and amygdala pathology in alpha-synuclein transgenic mice.","volume":"28","author":"Freichel","year":"2007","journal-title":"Neurobiol. Aging"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2019.03.054","article-title":"Hippocampal damage and white matter lesions contribute to cognitive impairment in MPTP-lesioned mice with chronic cerebral hypoperfusion.","volume":"368","author":"Gao","year":"2019","journal-title":"Behav. Brain Res."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/0306-4522(96)00202-3","article-title":"Spatial memory impairment induced by lesion of the mesohippocampal dopaminergic system in the rat.","volume":"74","author":"Gasbarri","year":"1996","journal-title":"Neuroscience"},{"key":"B55","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.neuroscience.2013.09.042","article-title":"Neuroprotective effects of swimming training in a mouse model of Parkinson\u2019s disease induced by 6-hydroxydopamine.","volume":"256","author":"Goes","year":"2014","journal-title":"Neuroscience"},{"key":"B56","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1093\/brain\/awu159","article-title":"Grey matter hypometabolism and atrophy in Parkinson\u2019s disease with cognitive impairment: a two-step process.","author":"Gonz\u00e1lez-Redondo","year":"2014","journal-title":"Brain"},{"key":"B57","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jneumeth.2018.08.012","article-title":"Animal models of early-stage Parkinson\u2019s disease and acute dopamine deficiency to study compensatory neurodegenerative mechanisms.","volume":"308","author":"Grandi","year":"2018","journal-title":"J. Neurosci. Methods"},{"key":"B58","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.brainres.2019.01.016","article-title":"The toxin MPTP generates similar cognitive and locomotor deficits in hTau and tau knock-out mice.","volume":"1711","author":"Gratuze","year":"2019","journal-title":"Brain Res."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1093\/brain\/awv104","article-title":"Parkinson\u2019s disease dementia: a neural networks perspective.","author":"Gratwicke","year":"2015","journal-title":"Brain"},{"key":"B60","doi-asserted-by":"publisher","first-page":"978","DOI":"10.3969\/j.issn.1673-5374.2012.13.003","article-title":"Intracerebroventricular transplanted bone marrow stem cells survive and migrate into the brain of rats with Parkinson\u2019s disease.","volume":"7","author":"Gu","year":"2012","journal-title":"Neural Regen. Res."},{"key":"B61","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1080\/01616412.2017.1352185","article-title":"The effect of orexin-A on motor and cognitive functions in a rat model of Parkinson\u2019s disease.","volume":"39","author":"Hadadianpour","year":"2017","journal-title":"Neurol. Res."},{"key":"B62","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.npep.2018.01.001","article-title":"Apelin-13 ameliorates cognitive impairments in 6-hydroxydopamine-induced substantia nigra lesion in rats.","volume":"68","author":"Haghparast","year":"2018","journal-title":"Neuropeptides"},{"key":"B63","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1002\/mds.26578","article-title":"Longitudinal measurements of cerebrospinal fluid biomarkers in Parkinson\u2019s disease.","volume":"31","author":"Hall","year":"2016","journal-title":"Mov. Disord."},{"key":"B64","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1002\/mds.25857","article-title":"The neurobiological basis of cognitive impairment in Parkinson\u2019s disease.","volume":"29","author":"Halliday","year":"2014","journal-title":"Mov. Disord."},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2021.627356","article-title":"Dopaminergic and metabolic correlations with cognitive domains in non-demented Parkinson\u2019s disease.","volume":"13","author":"Han","year":"2021","journal-title":"Front. Aging Neurosci."},{"key":"B66","doi-asserted-by":"publisher","first-page":"13518","DOI":"10.18632\/aging.103458","article-title":"Association of the serum microRNA-29 family with cognitive impairment in Parkinson\u2019s disease.","volume":"12","author":"Han","year":"2020","journal-title":"Aging (Albany N. Y.)"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2020.599045","article-title":"A comprehensive phenotype of non-motor impairments and distribution of alpha-synuclein deposition in Parkinsonism-induced mice by a combination injection of MPTP and probenecid.","volume":"12","author":"Han","year":"2020","journal-title":"Front. Aging Neurosci."},{"key":"B68","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/bpa.12769","article-title":"Small vessel disease pathological changes in neurodegenerative and vascular dementias concomitant with autonomic dysfunction.","volume":"30","author":"Hase","year":"2020","journal-title":"Brain Pathol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.amjmed.2019.03.001","article-title":"Parkinson\u2019s disease and parkinsonism.","volume":"132","author":"Hayes","year":"2019","journal-title":"Am. J. Med."},{"key":"B70","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.physbeh.2014.03.017","article-title":"Measuring attention in a Parkinson\u2019s disease rat model using the 5-arm maze test.","volume":"130","author":"Ho","year":"2014","journal-title":"Physiol. Behav."},{"key":"B71","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.bbr.2011.01.028","article-title":"Effects of D-cycloserine on MPTP-induced behavioral and neurological changes: potential for treatment of Parkinson\u2019s disease dementia.","volume":"219","author":"Ho","year":"2011","journal-title":"Behav. Brain Res."},{"key":"B72","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.neuroscience.2019.09.006","article-title":"Lesion of the locus coeruleus damages learning and memory performance in paraquat and maneb-induced mouse Parkinson\u2019s disease model.","volume":"419","author":"Hou","year":"2019","journal-title":"Neuroscience"},{"key":"B73","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.neures.2011.05.016","article-title":"Spatial memory deficits and oxidative stress damage following exposure to lipopolysaccharide in a rodent model of Parkinson\u2019s disease.","volume":"71","author":"Hritcu","year":"2011","journal-title":"Neurosci. Res."},{"key":"B74","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.bbr.2011.12.035","article-title":"Effects of MK-801 on recognition and neurodegeneration in an MPTP-induced Parkinson\u2019s rat model.","volume":"229","author":"Hsieh","year":"","journal-title":"Behav. Brain Res."},{"key":"B75","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.pbb.2012.03.022","article-title":"Blockade of metabotropic glutamate receptors inhibits cognition and neurodegeneration in an MPTP-induced Parkinson\u2019s disease rat model.","volume":"102","author":"Hsieh","year":"","journal-title":"Pharmacol. Biochem. Behav."},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2018.00091","article-title":"Medications used for cognitive enhancement in patients with Schizophrenia, Bipolar disorder, Alzheimer\u2019s disease, and Parkinson\u2019s disease.","volume":"9","author":"Hsu","year":"2018","journal-title":"Front. Psychiatry"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19020508","article-title":"Voluntary physical exercise improves subsequent motor and cognitive impairments in a rat model of Parkinson\u2019s disease.","volume":"19","author":"Hsueh","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"B78","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.bbr.2015.08.011","article-title":"Synergistic effects of ceftriaxone and erythropoietin on neuronal and behavioral deficits in an MPTP-induced animal model of Parkinson\u2019s disease dementia.","volume":"294","author":"Huang","year":"2015","journal-title":"Behav. Brain Res."},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20184432","article-title":"The role of lysosomes in a broad disease-modifying approach evaluated across transgenic mouse models of Alzheimer\u2019s disease and Parkinson\u2019s disease and models of mild cognitive impairment.","volume":"20","author":"Hwang","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B80","first-page":"555","article-title":"Repeated treatment with a low dose of reserpine as a progressive model of Parkinson\u2019s dementia.","volume":"32","author":"Ikram","year":"2019","journal-title":"Pak. J. Pharm. Sci."},{"key":"B81","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/s0165-0270(99)00184-3","article-title":"Comparison of eight clinical rating scales used for the assessment of MPTP-induced parkinsonism in the Macaque monkey.","volume":"96","author":"Imbert","year":"2000","journal-title":"J. Neurosci. Methods"},{"key":"B82","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1248\/bpb.34.92","article-title":"Parkinsonian rotenone mouse model: reevaluation of long-term administration of rotenone in C57BL\/6 mice.","volume":"34","author":"Inden","year":"2011","journal-title":"Biol. Pharm. Bull."},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2020.528809","article-title":"Molecular imaging of striatal dopaminergic neuronal loss and the neurovascular unit in Parkinson disease.","volume":"14","author":"Ivanidze","year":"2020","journal-title":"Front. Neurosci."},{"key":"B84","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/bs.irn.2016.12.001","article-title":"Cerebrospinal fluid biomarkers of cognitive decline in Parkinson\u2019s disease.","volume":"132","author":"Johar","year":"2017","journal-title":"Int. Rev. Neurobiol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s00213-013-3158-x","article-title":"Effects of the adenosine A2A antagonist istradefylline on cognitive performance in rats with a 6-OHDA lesion in prefrontal cortex.","volume":"230","author":"Kadowaki Horita","year":"2013","journal-title":"Psychopharmacology (Berl.)"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20215402","article-title":"Animal models for Parkinson\u2019s disease research: trends in the 2000s.","volume":"20","author":"Kin","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B87","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.bbr.2016.02.040","article-title":"Physical exercise counteracts MPTP-induced changes in neural precursor cell proliferation in the hippocampus and restores spatial learning but not memory performance in the water maze.","volume":"307","author":"Klein","year":"2016","journal-title":"Behav. Brain Res."},{"key":"B88","doi-asserted-by":"publisher","first-page":"196","DOI":"10.5935\/1984-0063.20190078","article-title":"Absence of a synergic nigral proapoptotic effect triggered by REM sleep deprivation in the rotenone model of Parkinson\u2019s disease.","volume":"12","author":"Kmita","year":"2019","journal-title":"Sleep Sci."},{"key":"B89","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1002\/mds.27991","article-title":"Neuropathological findings in Parkinson\u2019s disease with mild cognitive impairment.","volume":"35","author":"Knox","year":"2020","journal-title":"Mov. Disord."},{"key":"B90","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.neuropharm.2016.07.012","article-title":"An evaluation of istradefylline treatment on Parkinsonian motor and cognitive deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque models.","author":"Ko","year":"2016","journal-title":"Neuropharmacology"},{"key":"B91","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.bbr.2012.03.026","article-title":"\u03b1-Synuclein knockout mice have cognitive impairments.","volume":"231","author":"Kokhan","year":"2012","journal-title":"Behav. Brain Res."},{"key":"B92","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.neulet.2012.02.083","article-title":"Thalamic cholinergic innervation is spared in Alzheimer disease compared to parkinsonian disorders.","volume":"514","author":"Kotagal","year":"2012","journal-title":"Neurosci. Lett."},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-020-01083-5","article-title":"Neuroinflammation and protein pathology in Parkinson\u2019s disease dementia.","volume":"8","author":"Kouli","year":"2020","journal-title":"Acta Neuropathol. Commun."},{"key":"B94","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/nan.12644","article-title":"Peripheral inflammation exacerbates \u03b1-synuclein toxicity and neuropathology in Parkinson\u2019s models.","volume":"47","author":"La Vitola","year":"2021","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.bbi.2018.02.012","article-title":"Alpha-synuclein oligomers impair memory through glial cell activation and via Toll-like receptor 2.","volume":"69","author":"La Vitola","year":"2018","journal-title":"Brain Behav. Immun."},{"key":"B96","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1093\/brain\/awy318","article-title":"Cellular prion protein neither binds to alpha-synuclein oligomers nor mediates their detrimental effects.","volume":"142","author":"La Vitola","year":"2019","journal-title":"Brain"},{"key":"B97","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.brainresbull.2019.01.009","article-title":"Cognitive and anxiety-like impairments accompanied by serotonergic ultrastructural and immunohistochemical alterations in early stages of parkinsonism.","volume":"146","author":"Leal","year":"2019","journal-title":"Brain Res. Bull."},{"key":"B98","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/nm.2613","article-title":"Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export.","volume":"18","author":"Lei","year":"2012","journal-title":"Nat. Med."},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0071341","article-title":"Cognitive dysfunction precedes the onset of motor symptoms in the MitoPark mouse model of Parkinson\u2019s disease.","volume":"8","author":"Li","year":"2013","journal-title":"PLoS One"},{"key":"B100","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/mds.24893","article-title":"Diagnostic criteria for mild cognitive impairment in Parkinson\u2019s disease: movement disorder society task force guidelines.","volume":"27","author":"Litvan","year":"2012","journal-title":"Mov. Disord."},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-019-0717-3","article-title":"Hippocampal CA2 Lewy pathology is associated with cholinergic degeneration in Parkinson\u2019s disease with cognitive decline.","volume":"7","author":"Liu","year":"2019","journal-title":"Acta Neuropathol. Commun."},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/j.msec.2020.111028","article-title":"Actively targeted gold nanoparticle composites improve behavior and cognitive impairment in Parkinson\u2019s disease mice.","volume":"114","author":"Liu","year":"2020","journal-title":"Mater. Sci. Eng. C Mater. Biol. Appl."},{"key":"B103","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/gps.5222","article-title":"Serum levels of glial cell line-derived neurotrophic factor and multiple neurotransmitters: in relation to cognitive performance in Parkinson\u2019s disease with mild cognitive impairment.","volume":"35","author":"Liu","year":"2020","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2019.112031","article-title":"Sleep deprivation caused a memory defects and emotional changes in a rotenone-based zebrafish model of Parkinson\u2019s disease.","volume":"372","author":"Lv","year":"2019","journal-title":"Behav. Brain Res."},{"key":"B105","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1093\/brain\/awv211","article-title":"Baseline and longitudinal grey matter changes in newly diagnosed Parkinson\u2019s disease: ICICLE-PD study.","author":"Mak","year":"2015","journal-title":"Brain"},{"key":"B106","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.brainres.2018.03.035","article-title":"Limitations of the rat medial forebrain lesion model to study prefrontal cortex mediated cognitive tasks in Parkinson\u2019s disease.","volume":"1702","author":"Marshall","year":"2019","journal-title":"Brain Res."},{"key":"B107","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1002\/mds.26632","article-title":"Orthostatic hypotension and cognitive impairment in Parkinson\u2019s disease: causation or association?","volume":"31","author":"McDonald","year":"2016","journal-title":"Mov. Disord."},{"key":"B108","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1002\/jnr.23592","article-title":"Partial depletion of striatal dopamine enhances penetrance of cognitive deficits in a transgenic mouse model of Alzheimer\u2019s disease.","volume":"93","author":"Melief","year":"2015","journal-title":"J. Neurosci. Res."},{"key":"B109","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1017\/s1461145710000775","article-title":"The dopamine D3 receptor antagonist, S33138, counters cognitive impairment in a range of rodent and primate procedures.","volume":"13","author":"Millan","year":"2010","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1159\/000289227","article-title":"Social odor recognition: a novel behavioral model for cognitive dysfunction in Parkinson\u2019s disease.","volume":"7","author":"Monaghan","year":"2010","journal-title":"Neurodegener. Dis."},{"key":"B111","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1007\/s00415-018-8800-4","article-title":"Mild cognitive impairment in Parkinson\u2019s disease: the Parkinson\u2019s disease cognitive study (PACOS).","volume":"265","author":"Monastero","year":"2018","journal-title":"J. Neurol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.3727\/096368912x657242","article-title":"Stem cell grafting improves both motor and cognitive impairments in a genetic model of Parkinson\u2019s disease, the aphakia (ak) mouse.","volume":"22","author":"Moon","year":"2013","journal-title":"Cell Transplant."},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17091447","article-title":"Toxin-induced experimental models of learning and memory impairment.","volume":"17","author":"More","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"B114","first-page":"801","article-title":"NSAIDs ameliorate cognitive and motor impairment in a model of parkinsonism induced by chlorpromazine.","volume":"30","author":"Naeem","year":"2017","journal-title":"Pak. J. Pharm. Sci."},{"key":"B115","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.vascn.2016.10.003","article-title":"Early life exposure to permethrin: a progressive animal model of Parkinson\u2019s disease.","volume":"83","author":"Nasuti","year":"2017","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"B116","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.tox.2012.09.016","article-title":"Effects of early life permethrin exposure on spatial working memory and on monoamine levels in different brain areas of pre-senescent rats.","volume":"303","author":"Nasuti","year":"2013","journal-title":"Toxicology"},{"key":"B117","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1093\/hmg\/ddu748","article-title":"Early Parkinson\u2019s disease symptoms in \u03b1-synuclein transgenic monkeys.","volume":"24","author":"Niu","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"B118","doi-asserted-by":"publisher","first-page":"415","DOI":"10.3109\/01480545.2014.975355","article-title":"-NMDA R\/+VDR pharmacological phenotype as a novel therapeutic target in relieving motor-cognitive impairments in Parkinsonism.","volume":"38","author":"Ogundele","year":"2015","journal-title":"Drug Chem. Toxicol."},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2019.113110","article-title":"Depletion of hypothalamic hypocretin\/orexin neurons correlates with impaired memory in a Parkinson\u2019s disease animal model.","volume":"323","author":"Oliveira","year":"2020","journal-title":"Exp. Neurol."},{"key":"B120","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.parkreldis.2014.12.011","article-title":"Prognostic factors for early mortality in Parkinson\u2019s disease.","volume":"21","author":"Oosterveld","year":"2015","journal-title":"Parkinsonism Relat. Disord."},{"key":"B121","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1007\/s00415-012-6648-6","article-title":"Serum epidermal growth factor predicts cognitive functions in early, drug-naive Parkinson\u2019s disease patients.","volume":"260","author":"Pellecchia","year":"2013","journal-title":"J. Neurol."},{"key":"B122","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1002\/hbm.22822","article-title":"Aberrant cerebral network topology and mild cognitive impairment in early Parkinson\u2019s disease.","volume":"36","author":"Pereira","year":"2015","journal-title":"Hum. Brain Mapp."},{"key":"B123","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.neuro.2015.07.005","article-title":"Developmental exposure to manganese induces lasting motor and cognitive impairment in rats.","volume":"50","author":"Peres","year":"2015","journal-title":"Neurotoxicology"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2018.00237","article-title":"Additive effects of levodopa and a neurorestorative diet in a mouse model of Parkinson\u2019s disease.","volume":"10","author":"Perez-Pardo","year":"2018","journal-title":"Front. Aging Neurosci."},{"key":"B125","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.ejphar.2003.11.029","article-title":"Behavioural and neurochemical effects of phosphatidylserine in MPTP lesion of the substantia nigra of rats.","volume":"484","author":"Perry","year":"2004","journal-title":"Eur. J. Pharmacol."},{"key":"B126","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.bbr.2017.02.010","article-title":"Behavioral phenotypes associated with MPTP induction of partial lesions in common marmosets (Callithrix jacchus).","author":"Phillips","year":"2017","journal-title":"Behav. Brain Res."},{"key":"B127","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/bs.irn.2017.02.015","article-title":"Imaging in Parkinson\u2019s disease.","volume":"132","author":"Politis","year":"2017","journal-title":"Int. Rev. Neurobiol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1007\/s12640-009-9087-0","article-title":"Single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL\/6 mice models early preclinical phase of Parkinson\u2019s disease.","volume":"17","author":"Prediger","year":"2010","journal-title":"Neurotox. Res."},{"key":"B129","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1007\/s00702-010-0568-3","article-title":"Mice with genetic deletion of the heparin-binding growth factor midkine exhibit early preclinical features of Parkinson\u2019s disease.","volume":"118","author":"Prediger","year":"2011","journal-title":"J. Neural Transm. (Vienna)"},{"key":"B130","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.bbr.2012.04.020","article-title":"Long term behavioral effects of functional dopaminergic neurons generated from human neural stem cells in the rat 6-OH-DA Parkinson\u2019s disease model. Effects of the forced expression of BCL-X(L).","volume":"232","author":"Ramos-Moreno","year":"2012","journal-title":"Behav. Brain Res."},{"key":"B131","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1111\/j.1476-5381.2012.02100.x","article-title":"Exendin-4 reverts behavioural and neurochemical dysfunction in a pre-motor rodent model of Parkinson\u2019s disease with noradrenergic deficit.","volume":"167","author":"Rampersaud","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"B132","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1111\/fcp.12015","article-title":"Pharmacological blockade of TRPV1 receptors modulates the effects of 6-OHDA on motor and cognitive functions in a rat model of Parkinson\u2019s disease.","volume":"27","author":"Razavinasab","year":"2013","journal-title":"Fundam. Clin. Pharmacol."},{"key":"B133","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1177\/0271678x17750351","article-title":"Evaluation of exercise-induced modulation of glial activation and dopaminergic damage in a rat model of Parkinson\u2019s disease using [(11)C]PBR28 and [(18)F]FDOPA PET.","volume":"39","author":"Real","year":"2019","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"B134","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1002\/hbm.25393","article-title":"The default mode network and cognition in Parkinson\u2019s disease: a multimodal resting-state network approach.","volume":"42","author":"Ruppert","year":"2021","journal-title":"Hum. Brain Mapp."},{"key":"B135","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.bbi.2020.08.001","article-title":"Protective effect of Indole-3-carbinol, an NF-\u03baB inhibitor in experimental paradigm of Parkinson\u2019s disease: in silico and in vivo studies.","volume":"90","author":"Saini","year":"2020","journal-title":"Brain Behav. Immun."},{"key":"B136","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1080\/13607863.2020.1839860","article-title":"Vitamin D as a possible biomarker of mild cognitive impairment in parkinsonians.","volume":"25","author":"Santangelo","year":"2020","journal-title":"Aging Ment. Health"},{"key":"B137","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.parkreldis.2019.04.020","article-title":"Conversion to MCI and dementia in Parkinson\u2019s disease: a systematic review and meta-analysis.","volume":"65","author":"Saredakis","year":"2019","journal-title":"Parkinsonism Relat. Disord."},{"key":"B138","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/s0893-133x(01)00307-4","article-title":"Effects of the prolyl endopeptidase inhibitor S 17092 on cognitive deficits in chronic low dose MPTP-treated monkeys.","volume":"26","author":"Schneider","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"B139","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/0006-8993(90)90069-n","article-title":"Chronic exposure to low doses of MPTP. I. Cognitive deficits in motor asymptomatic monkeys.","volume":"519","author":"Schneider","year":"1990","journal-title":"Brain Res."},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2020.113514","article-title":"A novel dopamine D3R agonist SK609 with norepinephrine transporter inhibition promotes improvement in cognitive task performance in rodent and non-human primate models of Parkinson\u2019s disease.","volume":"335","author":"Schneider","year":"2021","journal-title":"Exp. Neurol."},{"key":"B141","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1002\/mds.25258","article-title":"Levodopa improves motor deficits but can further disrupt cognition in a macaque Parkinson model.","volume":"28","author":"Schneider","year":"2013","journal-title":"Mov. Disord."},{"key":"B142","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/1055-8330(95)90014-4","article-title":"Cognitive deficits precede motor deficits in a slowly progressing model of parkinsonism in the monkey.","volume":"4","author":"Schneider","year":"1995","journal-title":"Neurodegeneration"},{"key":"B143","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1093\/hmg\/ddt057","article-title":"Atp13a2-deficient mice exhibit neuronal ceroid lipofuscinosis, limited \u03b1-synuclein accumulation and age-dependent sensorimotor deficits.","volume":"22","author":"Schultheis","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.3390\/toxins10010016","article-title":"B -N-Methylamino-L-Alanine (BMAA) toxicity is gender and exposure-age dependent in rats.","volume":"10","author":"Scott","year":"2017","journal-title":"Toxins (Basel)"},{"key":"B145","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.neulet.2012.03.037","article-title":"Ibuprofen ameliorates protein aggregation and astrocytic gliosis, but not cognitive dysfunction, in a transgenic mouse expressing dementia with Lewy bodies-linked P123H \u03b2-synuclein.","volume":"515","author":"Sekiyama","year":"2012","journal-title":"Neurosci. Lett."},{"key":"B146","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s00401-019-02032-w","article-title":"Tau is required for progressive synaptic and memory deficits in a transgenic mouse model of \u03b1-synucleinopathy.","volume":"138","author":"Singh","year":"2019","journal-title":"Acta Neuropathol."},{"key":"B147","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s12035-016-0293-5","article-title":"Acetyl-L-carnitine via upegulating dopamine D1 receptor and attenuating microglial activation prevents neuronal loss and improves memory functions in Parkinsonian rats.","volume":"55","author":"Singh","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"B148","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1093\/hmg\/ddv628","article-title":"LRRK2 BAC transgenic rats develop progressive, L-DOPA-responsive motor impairment, and deficits in dopamine circuit function.","volume":"25","author":"Sloan","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"B149","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1136\/jnnp-2019-321111","article-title":"Neuropathology of dementia in patients with Parkinson\u2019s disease: a systematic review of autopsy studies.","volume":"90","author":"Smith","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B150","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.neuroscience.2017.07.001","article-title":"Daily consumption of methylene blue reduces attentional deficits and dopamine reduction in a 6-OHDA model of Parkinson\u2019s disease.","volume":"359","author":"Smith","year":"2017","journal-title":"Neuroscience"},{"key":"B151","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.parkreldis.2015.04.027","article-title":"Amyloid-\u03b2 and \u03b1-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson\u2019s disease.","volume":"21","author":"Stav","year":"2015","journal-title":"Parkinsonism Relat. Disord."},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2019.104708","article-title":"Behavioral defects associated with amygdala and cortical dysfunction in mice with seeded \u03b1-synuclein inclusions.","volume":"134","author":"Stoyka","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.4061\/2010\/238491","article-title":"Effects of SR141716A on cognitive and depression-related behavior in an animal model of premotor Parkinson\u2019s disease.","volume":"2010","author":"Tadaiesky","year":"2010","journal-title":"Parkinsons Dis."},{"key":"B154","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.neuroscience.2008.08.035","article-title":"Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson\u2019s disease.","volume":"156","author":"Tadaiesky","year":"2008","journal-title":"Neuroscience"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0240491","article-title":"The absence of orthostatic heart rate increase is associated with cognitive impairment in Parkinson\u2019s disease.","volume":"15","author":"Tanaka","year":"2020","journal-title":"PLoS One"},{"key":"B156","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.bbr.2017.11.008","article-title":"REM sleep deprivation and dopaminergic D2 receptors modulation increase recognition memory in an animal model of Parkinson\u2019s disease.","volume":"339","author":"Targa","year":"2018","journal-title":"Behav. Brain Res."},{"key":"B157","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1037\/\/0735-7044.104.4.564","article-title":"Cognitive and motor deficits in the performance of an object retrieval task with a barrier-detour in monkeys (Cercopithecus aethiops sabaeus) treated with MPTP: long-term performance and effect of transparency of the barrier.","volume":"104","author":"Taylor","year":"1990","journal-title":"Behav. Neurosci."},{"key":"B158","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1101\/lm.052126.120","article-title":"ApoE isoform-specific differences in behavior and cognition associated with subchronic MPTP exposure.","volume":"27","author":"Torres","year":"2020","journal-title":"Learn. Mem."},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0139694","article-title":"The progressive BSSG rat model of Parkinson\u2019s: recapitulating multiple key features of the human disease.","volume":"10","author":"Van Kampen","year":"2015","journal-title":"PLoS One"},{"key":"B160","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1007\/s00702-019-02043-7","article-title":"The contribution of cerebrovascular risk factors, metabolic and inflammatory changes to cognitive decline in Parkinson\u2019s disease: preliminary observations.","volume":"126","author":"Vesel\u00fd","year":"2019","journal-title":"J. Neural Transm. (Vienna)"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0023952","article-title":"Early presymptomatic and long-term changes of rest activity cycles and cognitive behavior in a MPTP-monkey model of Parkinson\u2019s disease.","volume":"6","author":"Vezoli","year":"2011","journal-title":"PLoS One"},{"key":"B162","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.bbr.2009.11.006","article-title":"Involvement of NMDA receptors in both MPTP-induced neuroinflammation and deficits in episodic-like memory in Wistar rats.","volume":"208","author":"Wang","year":"2010","journal-title":"Behav. Brain Res."},{"key":"B163","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.neuro.2021.01.002","article-title":"Taurine improves neuron injuries and cognitive impairment in a mouse Parkinson\u2019s disease model through inhibition of microglial activation.","volume":"83","author":"Wang","year":"2021","journal-title":"Neurotoxicology"},{"key":"B164","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1037\/a0017401","article-title":"MPTP lesion causes neuroinflammation and deficits in object recognition in Wistar rats.","volume":"123","author":"Wang","year":"2009","journal-title":"Behav. Neurosci."},{"key":"B165","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.neuroscience.2019.08.024","article-title":"Voltage-gated sodium channels are involved in cognitive impairments in Parkinson\u2019s disease- like Rats.","volume":"418","author":"Wang","year":"2019","journal-title":"Neuroscience"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2020.113284","article-title":"Mice deficient in GM1 manifest both motor and non-motor symptoms of Parkinson\u2019s disease; successful treatment with synthetic GM1 ganglioside.","volume":"329","author":"Wu","year":"2020","journal-title":"Exp. Neurol."},{"key":"B167","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.neuroscience.2013.11.051","article-title":"Nobiletin treatment improves motor and cognitive deficits seen in MPTP-induced Parkinson model mice.","volume":"259","author":"Yabuki","year":"2014","journal-title":"Neuroscience"},{"key":"B168","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jchemneu.2017.07.002","article-title":"Role of estrogen and levodopa in 1-methyl-4-pheny-l-1, 2, 3, 6-tetrahydropyridine (mptp)-induced cognitive deficit in Parkinsonian ovariectomized mice model: a comparative study.","volume":"85","author":"Yadav","year":"2017","journal-title":"J. Chem. Neuroanat."},{"key":"B169","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.bbrc.2020.03.097","article-title":"Bruceine D elevates Nrf2 activation to restrain Parkinson\u2019s disease in mice through suppressing oxidative stress and inflammatory response.","volume":"526","author":"Yang","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B170","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.3906\/sag-1408-68","article-title":"Impaired cognitive performance and hippocampal atrophy in Parkinson disease.","volume":"45","author":"Yildiz","year":"2015","journal-title":"Turk. J. Med. Sci."},{"key":"B171","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1002\/mds.25817","article-title":"ABT-089 and ABT-894 reduce levodopa-induced dyskinesias in a monkey model of Parkinson\u2019s disease.","volume":"29","author":"Zhang","year":"2014","journal-title":"Mov. Disord."},{"key":"B172","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1124\/jpet.113.207639","article-title":"Nicotinic receptor agonists reduce L-DOPA-induced dyskinesias in a monkey model of Parkinson\u2019s disease.","volume":"347","author":"Zhang","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2020.563054","article-title":"L-Asparaginase exerts neuroprotective effects in an SH-SY5Y-A53T model of Parkinson\u2019s disease by regulating glutamine metabolism.","volume":"13","author":"Zhang","year":"2020","journal-title":"Front. Mol. Neurosci."},{"key":"B174","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.freeradbiomed.2018.06.029","article-title":"Trx-1 ameliorates learning and memory deficits in MPTP-induced Parkinson\u2019s disease model in mice.","volume":"124","author":"Zhang","year":"2018","journal-title":"Free Radic. Biol. Med."},{"key":"B175","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.neuroimage.2017.05.066","article-title":"Altered adenosine 2A and dopamine D2 receptor availability in the 6-hydroxydopamine-treated rats with and without levodopa-induced dyskinesia.","volume":"157","author":"Zhou","year":"2017","journal-title":"Neuroimage"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2021.153578","article-title":"Lycorine, a natural alkaloid, promotes the degradation of alpha-synuclein via PKA-mediated UPS activation in transgenic Parkinson\u2019s disease models.","volume":"87","author":"Zhu","year":"2021","journal-title":"Phytomedicine"},{"key":"B177","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1242\/dmm.010363","article-title":"Cognitive effects of dopamine depletion in the context of diminished acetylcholine signaling capacity in mice.","volume":"6","author":"Zurkovsky","year":"2013","journal-title":"Dis. Model Mech."}],"updated-by":[{"DOI":"10.3389\/fnagi.2021.827753","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T00:00:00Z","timestamp":1640044800000}}],"container-title":["Frontiers in Aging Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2021.745438\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T16:23:52Z","timestamp":1640017432000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2021.745438\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,29]]},"references-count":177,"alternative-id":["10.3389\/fnagi.2021.745438"],"URL":"https:\/\/doi.org\/10.3389\/fnagi.2021.745438","relation":{"corrigendum":[{"id-type":"doi","id":"10.3389\/fnagi.2021.827753","asserted-by":"object"}]},"ISSN":["1663-4365"],"issn-type":[{"value":"1663-4365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,29]]},"article-number":"745438"}}